Credit: shisu_ka/Shutterstock. Magnet Biomedicine has entered a partnership and licence agreement with Eli Lilly to discover, develop and commercialise oncology molecular glue therapeutics. The ...

Other pharmas have also put big money into the glue game. In 2024, Eisai signed its own Seed pact worth up to $1.5 billion to go after neurodegeneration and oncology targets.

Starting with the September 2025 intake, the application period and screening process for Non-Degree Students, which previously differed between domestic and international applicants, have been ...